Centre for In Vivo Modelling Service Core

At the Centre for In Vivo Modelling (CIVM), we combine advanced animal genetics and cutting-edge technologies to drive cancer research. Our multidisciplinary team specialises in the generation and maintenance of genetically engineered mouse models (GEMMs), humanised mouse strains, and patient-derived models (xenografts and organoids), using innovations such as CRISPR gene editing, embryo manipulation, and in vivo genetic screening. We develop and cryopreserve new cancer models that closely replicate human disease, supporting translational studies that inform effective therapies. Our approach integrates rigorous scientific standards, ethical oversight, and collaborative expertise, aiming to accelerate progress in understanding cancer biology and developing better treatments for patients.

Our Centre is dedicated to driving innovation and excellence in cancer research through advanced in vivo modelling. We work in close collaboration with the ICR researchers and clinicians at The Royal Marsden to generate genetically engineered mouse models (GEMMs) and patient-derived models, such as patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) to interrogate cancer biology in its own ecosystem. By leveraging these sophisticated in vivo systems, the Centre aims to:

  • Develop innovative cancer models in collaboration with ICR researchers to advance cancer research and drug discovery.
  • Work in partnership with The Royal Marsden Hospital to obtain patient samples and generate new patient-derived cancer models for translational studies.
  • Foster close interdisciplinary collaboration with drug discovery teams to leverage these in vivo models in the creation and testing of next-generation anti-cancer therapies.
  • Continuously improve the sophistication and relevance of our cancer models, ensuring they more faithfully recapitulate the complexity of human disease and enhance the translational impact of our research.

 

Our services

Advantages of cryopreserving your strains:

  • Allows you to save space, by getting the mice you need, when you need;
  • Reduces your animal costs;
  • Reduces animal use;
  • Reduces risk from disasters (e.g. disease outbreaks, breeding cessation, equipment failures, genetic contamination, natural disasters, etc…).

 What can be cryopreserved?

  • Mouse Sperm
  • Mouse Embryos
  • Mouse Embryonic Stem Cells
  • Mouse Oocytes

 Sperm Cryopreservation:

Description: Sperm is retrieved from the epididymal tissues of 3 male mice and is cryopreserved in 20 to 30 straws that are stored in liquid-phase, liquid nitrogen across two tanks in two separate locations (SRD and CCDD), to ensure sample safety and mitigate risks associated to unexpected or uncontrollable events.

Material needed: 3 males, reproductively active, 12-25 weeks old

Timeline: 2-6 weeks (dependant on QC method of choice)

Considerations: this method of cryopreservation is rapid and cheap; however, it only preserves half of the genome. This method is only recommended for single mutations on a common inbred background.

Quality Control: we provide different levels of Quality Control (QC) for different price ranges.

  1. Test thaw QC: we will thaw 1 straw the day after cryopreservation and visually assess motility and viability of the recovered sperm
  2. IVF and culture to blastocyst QC: we highly recommend this QC step. In addition to test thaw, we will also perform IVF and culture embryos up to blastocyst stage. We will provide the investigator with a fertility rate (%) for the recovered sperm. We will charge an extra cost to cover the IVF procedure.
  3. IVF and embryo transfer QC: In addition to test thaw, we will perform IVF and transfer 2-cell embryos into up to 3 pseudopregnant females to generate viable embryos/live pups. We will charge an extra cost to cover the IVF and embryo transfer procedures.

    Please note that we require you to provide your genotyping protocol, as well as full detail of the genetic content of each strain that you submit for cryopreservation.

Diagram of Sperm Cryopreservation

Embryo Cryopreservation:

Description: Female mice are hormonally superovulated and oocytes are retrieved for in vitro fertilisation (IVF) with sperm from donor male. Resulting embryos are placed in cryoprotectant and loaded into multiple straws, which are gradually cooled and stored in liquid-phase liquid nitrogen in two separate tanks.

Material needed: Donor male and 8-10 donor females

Timeline: 12-15 weeks

Diagram of Embryo Cryopreservation

Embryonic Stem Cells Cryopreservation:

Not available, yet.

Oocyte Cryopreservation:

Not available, yet.

Cryostorage:

If you have cryopreserved mouse sperm/embryo/oocytes at another institution, we can cryostorage your samples for an annual fee. We do require that the investigator takes charge of shipping costs into our facility, and that thawing and genotyping protocols are submitted to the CIVM.

The CIVM stores all samples in liquid-phase liquid nitrogen tanks (CryoPlus1, ThermoFisher Scientific). Material retrieved from each strain is split between 2 tanks, a main and a backup tank, for redundancy. For additional safety, these 2 tanks are located in two separate buildings at ICR Sutton. Both tanks are continuously monitored by T-scan alarm systems and undergo annual service, as well as daily visual inspections.


 

Sperm Cryorecovery:

Description: Frozen sperm is cryorecovered by IVF, followed by embryo transfer. We can purchase wild-type female oocyte donors of the same genetic background, or alternatively the investigator can provide homozygous oocyte donors of the same strain.

Material needed: straw with frozen sperm and 8 to 12 females for IVF, 7-16 weeks old.

Timeline: 12-15 weeks

Diagram of Sperm Cryorecovery

 

Embryo Cryorecovery:

Description: Frozen 2-cell embryos are thawed and transferred into pseudopregnant females.

Material needed: straw(s) with frozen 2-cell embryos

Timeline: 8-10 week


Oocyte Cryorecovery:

Not available, yet.

 

Mouse rederivation

Description: Mouse rederivation is a process used to produce pathogen-free mouse colonies by removing microbial contaminants from existing lines. The procedure can be performed either through natural mating or in vitro fertilization (IVF):

  • In natural mating, embryos are obtained from donor mice and transferred into pathogen-free recipient females.
  • In IVF-based rederivation, fertilized embryos are created in vitro using gametes from donor mice and then implanted into clean recipient females.

Both methods effectively eliminate pathogens, allowing safe importation of mouse strains from lower health-status facilities into the ICR BSU. Samples from both litter and recipient mother will be sent for Health Screening and the associated costs will be charged separately to the Investigator.

Material needed: For IVF-based rederivation we require the investigator to provide 2 males, reproductively active, 12-25 weeks old, and the CIVM will purchase wild-type female egg-donors. Alternatively, if maintaining homozygosity is essential, the investigator will need to provide additional 6-10 females, 7-16 weeks old.

Timeline: 12-15 week

Mouse Rederivation Mating Diagram

Mouse Rederivation IVF diagram

We are currently setting up CRISPR/Cas9-based gene editing protocols. Soon, you’ll be able to apply for projects that involve developing new alleles based on:

  • Knockout by indel formation
  • Knockout by precise deletion
  • Conditional knockout
  • Knock-in of point mutations
  • Knock-in of small tags
  • Large knock-in
  • Exon replacement

These alleles will be developed based on Electroporation of Microinjection of CRISPR/Cas9 system reagents.

We will collaborate with you to design the best strategy and help you generate the genetically engineered mice you need for your project. 

We also provide:

  • Development of humanised mouse strains
  • Development of Patient-derived xenografts (PDX) and organoid models

Latest ICR News

05/03/26 - by

Professor Robin Weiss, recognised as one of the most influential scientists in modern virology and cancer biology, passed away on 27 February 2026.

A former Director of The Institute of Cancer Research, London, Professor Weiss made discoveries that reshaped our understanding of retroviruses, HIV and virus associated cancers. His decades of leadership and scientific vision transformed the field and left an enduring legacy that continues to guide researchers today.

Professor Weiss first joined The Institute of Cancer Research (ICR) in 1980, beginning a pivotal chapter in both his career and the institute’s history. He served as Director, which was equivalent to the role of Chief Executive, from 1980 to 1989, and then continued as Director of Research for nine years.

His tenure was marked by bold scientific ambition, a commitment to interdisciplinary progress and an unwavering belief in prioritising research that could deliver tangible benefits for people affected by cancer.

A career full of highlights

Much of Professor Weiss’ most celebrated scientific work took place at the ICR. His research into retroviruses advanced global understanding of how viruses contribute to cancer, and his later pivot into HIV research resulted in discoveries that would prove foundational in the global fight against AIDS.

His most significant achievements included identifying CD4 as the receptor used by HIV to enter human cells, a breakthrough that profoundly shaped subsequent diagnostic, therapeutic and vaccine research. After developing a cell line that served as a common laboratory model for studying virus replication and cell death, he was also the first scientist to demonstrate neutralising antibodies against HIV. Later, his work on a UK HIV isolate named CBL-1 – named after the ICR’s Chester Beatty Laboratories – allowed his colleague Richard Tedder to develop an assay to test for antibodies to HIV, which was subsequently successfully commercialised by the Wellcome Foundation.

In the field of cancer, Professor Weiss helped establish the role that viruses can play in the development of some forms of cancer. Professor Weiss was also part of the team that discovered the NRAS gene, which plays a key part in modulating cell division and is dysregulated in many cancers. NRAS is now considered a key biomarker and is used to guide treatment decisions in various types of cancer, including colorectal cancer and melanoma.

In recognition of his groundbreaking contributions, Professor Weiss received numerous honours throughout his career. These included being elected to the European Molecular Biology Organization (EMBO), becoming a Fellow of the Royal Society and being made an Honorary Fellow of the Royal College of Physicians. His work on retroviruses earned him the M. W. Beijerinck Prize for Virology, and in 2007, he received the prestigious Ernst Chain Prize, awarded by Imperial College London to scientists whose work has substantially advanced the understanding or management of human disease.

Professor Weiss also served as Editor-in-Chief of the British Journal of Cancer for several years. Under his guidance, it evolved into a multidisciplinary journal focused on research that directly benefits patients – a reflection of his deep commitment to ensuring that scientific discovery serves human health.

A wider impact on the research community

Beyond his own laboratory achievements, Professor Weiss was a mentor and advisor to generations of researchers.

Professor Sir Mel Greaves, Founding Director of the Centre for Evolution and Cancer at The Institute of Cancer Research, London, said:

"Robin Weiss was extremely influential in my scientific career. Always ahead of me, we tracked together at UCL as students, then at the Imperial Cancer Research Fund and then finally at the ICR. Robin, as ICR Director, recruited me and was always both inspirational and highly supportive at a personal level.

"I witnessed first-hand how Robin transformed the ICR in the 1980s by introducing cell and molecular biology, setting it on its current path to eminence and success. We all owe Robin a huge debt."

Professor Weiss’ influence extended globally through major collaborations, including research supported by the Gates Foundation, where he helped lead efforts towards HIV vaccine development. His curiosity and dedication also led him to investigate emerging viral threats, such as severe acute respiratory syndrome (SARS) and viruses relevant to xenotransplantation, demonstrating his agility as a scientist.

Professor Jonathan Weber, Professor of Communicable Diseases at Imperial College London and Co-Director of the Research Hub at the Pears Cumbria School of Medicine in Carlisle, worked closely with Professor Weiss for many years. Having looked after people with AIDS as a junior doctor at St Mary’s Hospital, London, Professor Weber was funded by the Wellcome Trust to join the Chester Beatty Labs at the ICR and be trained in retrovirology by Professor Weiss.

Professor Weber said:

"Robin’s laboratory, throughout the late 1980s, was the most stimulating scientific environment at the most extraordinary time. Of the 10 students and postdocs in his lab over the three years I spent there, all went on to professorial university posts in the UK, USA and Europe. His scientific opinion was widely sought and generously given; he encouraged endless scientific visitors, and his lab felt at the very epicentre of the international scientific effort to contain and control the HIV pandemic.

"40 years later, I still reminisce over that extraordinary period under Robin’s wise, forgiving and guiding hand."

A long-lasting legacy at the ICR

Professor Weiss also personally recruited Professor Chris Marshall and Professor Alan Hall to the ICR, both of whom were responsible for molecular oncology publications that laid the scientific basis for significant therapeutic developments decades later.

Professor Kristian Helin, Chief Executive of the ICR, said:

"Professor Weiss oversaw a transformational era for the ICR, strengthening its international reputation and fostering research that pushed the boundaries of what was thought possible. His work laid crucial foundations for new approaches to understanding the links between viruses and cancer, and he championed the development of the institute’s scientific culture – one defined by curiosity, rigour and collaboration."